293 related articles for article (PubMed ID: 15665279)
1. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
4. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells.
Wetherill YB; Petre CE; Monk KR; Puga A; Knudsen KE
Mol Cancer Ther; 2002 May; 1(7):515-24. PubMed ID: 12479269
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
[TBL] [Abstract][Full Text] [Related]
6. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
7. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
10. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
Zhao XY; Malloy PJ; Krishnan AV; Swami S; Navone NM; Peehl DM; Feldman D
Nat Med; 2000 Jun; 6(6):703-6. PubMed ID: 10835690
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival.
Sun C; Shi Y; Xu LL; Nageswararao C; Davis LD; Segawa T; Dobi A; McLeod DG; Srivastava S
Oncogene; 2006 Jun; 25(28):3905-13. PubMed ID: 16636679
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia increases androgen receptor activity in prostate cancer cells.
Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
[TBL] [Abstract][Full Text] [Related]
16. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
17. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
Hess-Wilson JK; Webb SL; Daly HK; Leung YK; Boldison J; Comstock CE; Sartor MA; Ho SM; Knudsen KE
Environ Health Perspect; 2007 Nov; 115(11):1646-53. PubMed ID: 18007998
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
19. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
